(2) A local
health officer must transmit by telephone or secure electronic means to the
department the information required by ARM
37.114.205(1) and
(2) for each suspected or confirmed case of
one of the following diseases, within the time limit noted for each:
(a) Information about a case of one of the
following diseases should be submitted within 24 hours after it is received by
the local health officer:
(i) an outbreak of
a disease or condition specified in ARM
37.114.203;
(ii) any unusual incident of illness or death
in a human or animal with potential human health implications;
(iii) Acute flaccid myelitis (AFM);
(iv) Brucellosis;
(v) Cronobacter in infants;
(vi) Diphtheria;
(vii) Gastroenteritis outbreak;
(viii) Influenza-associated hospitalization
and mortality;
(ix)
Measles;
(x) Melioidosis;
(xi) Mpox;
(xii) Rabies in a human;
(xiii) Rabies in an animal;
(xiv) Rubella; and
(xv) Syphilis.
(b) Information about a case of one of the
following diseases must be submitted within seven calendar days after it is
received by the local health officer:
(i) AIDS
or HIV infection;
(ii) Arboviral
diseases, neuroinvasive and non-neuroinvasive (California serogroup,
Chikungunya, Eastern equine encephalitis, Powassan, Saint Louis encephalitis,
West Nile virus, Western equine encephalitis, Zika virus infection);
(iii) Arsenic poisoning (>= 70 µg/L
total arsenic in urine; or >= 35 µg/L methylated plus inorganic
arsenic in urine);
(iv)
Babesiosis;
(v) Cadmium poisoning
(>= five µg/L total blood cadmium levels; or >= three µg/L
total cadmium in urine);
(vi)
Campylobacteriosis;
(vii) Candida
auris (C. auris);
(viii)
Carbapenemase-producing carbapenem-resistant organisms (CP-CRO);
(ix) Chancroid;
(x) Chlamydial trachomatis
infection;
(xi) Cholera;
(xii) Coccidioidomycosis;
(xiii) Colorado tick fever;
(xiv) Coronavirus Disease 2019
(COVID-19);
(xv)
Cryptosporidiosis;
(xvi)
Cyclosporiasis;
(xvii) Dengue virus
infections;
(xviii) Escherichia
coli, Shiga toxin-producing (STEC);
(xix) Giardiasis;
(xx) Gonorrhea;
(xxi) Granuloma inguinale;
(xxii) Group A Streptococcus, invasive
disease;
(xxiii) Haemophilus
influenzae, invasive disease;
(xxiv) Hansen's disease (leprosy);
(xxv) Hantavirus pulmonary syndrome or
infection;
(xxvi) Hemolytic uremic
syndrome, post diarrheal;
(xxvii)
Hepatitis A, acute;
(xxviii)
Hepatitis B, acute, chronic, perinatal;
(xxix) Hepatitis C, acute, chronic;
(xxx) Lead levels in a capillary blood
specimen of >= 3.5 micrograms per deciliter(µg/dL) in a person less
than 16 years of age;
(xxxi) Lead
levels in a venous blood specimen at any level;
(xxxii) Legionellosis;
(xxxiii) Leptospirosis;
(xxxiv) Listeriosis;
(xxxv) Lyme disease;
(xxxvi) Malaria;
(xxxvii) Meningococcal disease (Neisseria
meningitidis);
(xxxviii) Mercury
poisoning (>= ten µg/L total mercury in urine; or >= ten µg
elemental mercury/g in creatinine in urine; or >= ten µg/L elemental,
organic, and inorganic blood mercury levels);
(xxxix) Multisystem inflammatory syndrome in
children (MIS-C);
(xl)
Mumps;
(xli) Pertussis;
(xlii) Psittacosis;
(xliii) Q-fever (acute and
chronic);
(xliv) Rickettsial
diseases (including spotted fevers, flea-borne typhus, scrub typhus,
anaplasmosis, and ehrlichiosis);
(xlv) Salmonella Paratyphi
infection;
(xlvi) Salmonella Typhi
infection;
(xlvii)
Salmonellosis;
(xlviii)
Shigellosis;
(xlix) Streptococcus
pneumoniae, invasive disease;
(l)
Streptococcal toxic shock syndrome (STSS);
(li) Tetanus;
(lii) Tickborne relapsing fevers;
(liii) Toxic shock syndrome
(nonstreptococcal) (TSS);
(liv)
Transmissible spongiform encephalopathies;
(lv) Trichinellosis (trichinosis);
(lvi) Tuberculosis (TB) including latent
tuberculosis infection;
(lvii)
Varicella (chickenpox);
(lviii)
Vibriosis; and
(lix) Yellow
fever.